Does Rallies show Form 4 insider transactions for LXEO?

Yes. Rallies tracks LXEO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LXEO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LXEO. It does not provide personalized investment advice.

LXEO (Lexeo Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Lexeo Therapeutics, Inc. Common Stock (LXEO) is a publicly traded Healthcare sector company. As of May 21, 2026, LXEO trades at $5.34 with a market cap of $369.84M and a P/E ratio of -2.67. LXEO moved +14.51% today. Year to date, LXEO is -45.76%; over the trailing twelve months it is +45.04%. Its 52-week range spans $1.45 to $11.72. Analyst consensus is strong buy with an average price target of $18.60. Rallies surfaces LXEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LXEO stock inside the company?

Recent LXEO insider activity includes Townsend Richard Nolan sold 55.00K, Otero Jose Manuel sold 3.02K, Townsend Richard Nolan sold 10.17K, Otero Jose Manuel sold 721, and Townsend Richard Nolan sold 1.13K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LXEO Key Metrics

Key financial metrics for LXEO
Metric	Value
Price	$5.34
Market Cap	$369.84M
P/E Ratio	-2.67
EPS	$-1.86
Dividend Yield	0.00%
52-Week High	$11.72
52-Week Low	$1.45
Volume	10
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-99.96M
Gross Margin	0.00%

Recent LXEO Insider Trades

Townsend Richard Nolan sold 55.00K (~$313.14K) on Apr 6, 2026.
Otero Jose Manuel sold 3.02K (~$19.29K) on Feb 18, 2026.
Townsend Richard Nolan sold 10.17K (~$64.92K) on Feb 18, 2026.
Otero Jose Manuel sold 721 (~$6.68K) on Nov 18, 2025.
Townsend Richard Nolan sold 1.13K (~$10.45K) on Nov 18, 2025.

Latest LXEO News

Lexeo Unveils Porcine TNNI3 Model and 10L-200L AAV Scale-Up at ASGCT — Apr 27, 2026
Lexeo’s LX2006 Shows LVMI, Troponin Declines; LX2020 Cuts VT by 60% — Feb 28, 2026
Lexeo Details 30% LV Mass Reduction, FDA OKs Pooled Phase I/II for LX2006 — Feb 14, 2026

LXEO Analyst Consensus

5 analysts cover LXEO: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $18.60.

Common questions about LXEO

Who is trading LXEO stock inside the company?: Recent LXEO insider activity includes Townsend Richard Nolan sold 55.00K, Otero Jose Manuel sold 3.02K, Townsend Richard Nolan sold 10.17K, Otero Jose Manuel sold 721, and Townsend Richard Nolan sold 1.13K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LXEO?: Yes. Rallies tracks LXEO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LXEO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LXEO. It does not provide personalized investment advice.